Tasly Pharmaceutical Hits Day Low of CNY 13.20 Amid Price Pressure

Tasly Pharmaceutical Group Co., Ltd. experienced a notable decline today, with the stock dropping by 3.29% and reaching an intraday low of CNY 13.20. This performance stands in contrast to the China Shanghai Composite, which saw a modest gain of 0.5% on the same day. Over the past week, Tasly's stock has decreased by 4.61%, and its one-month performance reflects a decline of 5.97%. The company has faced significant challenges over the past year, with a total drop of 15.46%, while the broader market has gained 18.87%. Year-to-date, Tasly's performance is down 12.21%, compared to a 3.16% increase in the China Shanghai Composite. Financial metrics indicate that Tasly has struggled with long-term growth, as evidenced by a net sales decline of 9.48% annually over the last five years. The company's operating profit has also decreased by 2.22% during the same period. Additionally, recent financial results show a significant drop in net profit, falling by 55.59% to CNY 112.86 million. With a market capitalization of CNY 20,981 million, Tasly continues to navigate a challenging landscape in the pharmaceuticals and biotechnology sector.